Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis

Arthritis and Rheumatology

Volumn 71, Issue 7, 2019, Pages 1042-1055

  Taylor, Peter C ^a   Weinblatt, Michael E ^b   Burmester, Gerd R ^c   Rooney, Terence P ^d   Witt, Sarah ^d   Walls, Chad D ^d   Issa, Maher ^d   Salinas, Claudia A ^d   Saifan, Chadi ^d   Zhang, Xin ^d   Cardoso, Anabela ^d   González Gay, Miguel A ^e,f   Takeuchi, Tsutomu ^g  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d ELI LILLY AND COMPANY   (United States)

^e HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^f UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^g KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BARICITINIB; AZETIDINE DERIVATIVE; JANUS KINASE INHIBITOR; SULFONAMIDE;

ADULT; AGED; ARTERIAL THROMBOEMBOLISM; ARTICLE; CARDIOVASCULAR DISEASE; CONGESTIVE HEART FAILURE; DEEP VEIN THROMBOSIS; DRUG DOSE COMPARISON; DRUG SAFETY; DRUG WITHDRAWAL; EVALUATION STUDY; FEMALE; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MEDICAL DICTIONARY FOR REGULATORY ACTIVITIES; MIDDLE AGED; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; VENOUS THROMBOEMBOLISM; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL (TOPIC); HEART FAILURE; HEART INFARCTION; MORTALITY; THROMBOSIS; VEIN THROMBOSIS;

ADULT; AGED; ARTHRITIS, RHEUMATOID; AZETIDINES; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; FEMALE; HEART FAILURE; HUMANS; JANUS KINASE INHIBITORS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PULMONARY EMBOLISM; STROKE; SULFONAMIDES; THROMBOSIS; VENOUS THROMBOSIS;

EID: 85066808816     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.40841     Document Type: Article

References (52)

1. Fleischmann R, Schiff M, van der Heijde D, Ramos-Remus C, Spindler A, Stanislav M, et al. Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheumatol 2017;69:506–17.
2. Taylor PC, Keystone EC, van der Heijde D, Weinblatt ME, del Carmen Morales L, Reyes Gonzaga J, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med 2017;376:652–62.
3. Dougados M, van der Heijde D, Chen YC, Greenwald M, Drescher E, Liu J, et al. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis 2017;76:88–95.
4. Genovese MC, Kremer J, Zamani O, Ludivico C, Krogulec M, Xie L, et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med 2016;374:1243–52.
5. Fridman JS, Scherle PA, Collins R, Burn TC, Li Y, Li J, et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol 2010;184:5298–307.
6. Schieir O, Tosevski C, Glazier RH, Hogg-Johnson S, Badley EM. Incident myocardial infarction associated with major types of arthritis in the general population: a systematic review and meta-analysis. Ann Rheum Dis 2017;76:1396–404.
7. Holmqvist ME, Neovius M, Eriksson J, Mantel A, Wallberg-Jonsson S, Jacobsson LT, et al. Risk of venous thromboembolism in patients with rheumatoid arthritis and association with disease duration and hospitalization. JAMA 2012;308:1350–6.
8. Kim SC, Schneeweiss S, Liu J, Solomon DH. Risk of venous thromboembolism in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2013;65:1600–7.
9. Lee JJ, Pope JE. A meta-analysis of the risk of venous thromboembolism in inflammatory rheumatic diseases. Arthritis Res Ther 2014;16:435.
10. Corrales A, Gonzalez-Juanatey C, Peiro ME, Blanco R, Llorca J, Gonzalez-Gay MA. Carotid ultrasound is useful for the cardiovascular risk stratification of patients with rheumatoid arthritis: results of a population-based study. Ann Rheum Dis 2014;73:722–7.
11. Castaneda S, Nurmohamed MT, Gonzalez-Gay MA. Cardiovascular disease in inflammatory rheumatic diseases. Best Pract Res Clin Rheumatol 2016;30:851–69.
12. Meune C, Touze E, Trinquart L, Allanore Y. Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford) 2009;48:1309–13.
13. Del Rincón ID, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001;44:2737–45.
14. Lopez-Mejias R, Castaneda S, Gonzalez-Juanatey C, Corrales A, Ferraz-Amaro I, Genre F, et al. Cardiovascular risk assessment in patients with rheumatoid arthritis: the relevance of clinical, genetic and serological markers. Autoimmun Rev 2016;15:1013–30.
15. Matta F, Singala R, Yaekoub AY, Najjar R, Stein PD. Risk of venous thromboembolism with rheumatoid arthritis. Thromb Haemost 2009;101:134–8.
16. Chung WS, Peng CL, Lin CL, Chang YJ, Chen YF, Chiang JY, et al. Rheumatoid arthritis increases the risk of deep vein thrombosis and pulmonary thromboembolism: a nationwide cohort study. Ann Rheum Dis 2014;73:1774–80.
17. Ungprasert P, Srivali N, Spanuchart I, Thongprayoon C, Knight EL. Risk of venous thromboembolism in patients with rheumatoid arthritis: a systematic review and meta-analysis. Clin Rheumatol 2014;33:297–304.
18. Payne C, Zhang X, Shahri N, Williams W, Cannady E. Evaluation of potential drug-drug interactions with baricitinib [abstract]. Ann Rheum Dis 2015;74 Suppl 2:1063.
19. Keystone EC, Taylor PC, Drescher E, Schlichting DE, Beattie SD, Berclaz PY, et al. Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. Ann Rheum Dis 2015;74:333–40.
20. Tanaka Y, Emoto K, Cai Z, Aoki T, Schlichting D, Rooney T, et al. Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis receiving background methotrexate therapy: a 12-week, double-blind, randomized placebo-controlled study. J Rheumatol 2016;43:504–11.
21. Takeuchi T, Genovese MC, Haraoui B, Li Z, Xie L, Klar R, et al. Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study. Ann Rheum Dis 2019;78:171–8.
22. Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005;23 Suppl 39:S100–8.
23. Baber N. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Br J Clin Pharmacol 1994;37:401–4.
24. Zhang X, Chua L, Ernest C II, Macias W, Rooney T, Tham LS. Dose/exposure-response modeling to support dosing recommendation for phase III development of baricitinib in patients with rheumatoid arthritis. CPT Pharmacometrics Syst Pharmacol 2017;6:804–13.
25. Prevoo ML, van ’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight–joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44–8.
26. Taylor PC, Kremer JM, Emery P, Zuckerman SH, Ruotolo G, Zhong J, et al. Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies. Ann Rheum Dis 2018;77:988–95.
27. Kremer JM, Huizinga T, Chen L, Saifan CG, Issa M, Witt SL, et al. Analysis of neutrophils, lymphocytes, and platelets in pooled phase 2 and phase 3 studies of baricitinib for rheumatoid arthritis [abstract]. Ann Rheum Dis 2017;76:512.
28. Ogdie A, Kay McGill N, Shin DB, Takeshita J, Jon Love T, Noe MH, et al. Risk of venous thromboembolism in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a general population-based cohort study. Eur Heart J 2018;39:3608–14.
29. Choi HK, Rho YH, Zhu Y, Cea-Soriano L, Avina-Zubieta JA, Zhang Y. The risk of pulmonary embolism and deep vein thrombosis in rheumatoid arthritis: a UK population-based outpatient cohort study. Ann Rheum Dis 2013;72:1182–7.
30. Bacani AK, Gabriel SE, Crowson CS, Heit JA, Matteson EL. Noncardiac vascular disease in rheumatoid arthritis: increase in venous thromboembolic events? Arthritis Rheum 2012;64:53–61.
31. Davies R, Galloway JB, Watson KD, Lunt M, Symmons DP, Hyrich KL, et al. Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011;70:1831–4.
32. Eriksson JK, Jacobsson L, Bengtsson K, Askling J. Is ankylosing spondylitis a risk factor for cardiovascular disease, and how do these risks compare with those in rheumatoid arthritis? Ann Rheum Dis 2017;76:364–70.
33. Yusuf HR, Hooper WC, Grosse SD, Parker CS, Boulet SL, Ortel TL. Risk of venous thromboembolism occurrence among adults with selected autoimmune diseases: a study among a U.S. cohort of commercial insurance enrollees. Thromb Res 2015;135:50–7.
34. Romero-Diaz J, Garcia-Sosa I, Sanchez-Guerrero J. Thrombosis in systemic lupus erythematosus and other autoimmune diseases of recent onset. J Rheumatol 2009;36:68–75.
35. Charles-Schoeman C, Wicker P, Gonzalez-Gay MA, Boy M, Zuckerman A, Soma K, et al. Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor. Semin Arthritis Rheum 2016;46:261–71.
36. Giles JT, Sattar N, Gabriel SE, Ridker PM, Gay S, Warne C, et al. Comparative cardiovascular safety of tocilizumab vs etanercept in rheumatoid arthritis: results of a randomized, parallel-group, multicenter, noninferiority, phase 4 clinical trial [abstract]. Arthritis Rheumatol 2016;68 Suppl 10. URL: https://acrabstracts.org/abstract/comparative-cardiovascular-safety-of-tocilizumab-vs-etanercept-in-rheumatoid-arthritis-results-of-a-randomized-parallel-group-multicenter-noninferiority-phase-4-clinical-trial/.
37. Kim SC, Solomon DH, Rogers JR, Gale S, Klearman M, Sarsour K, et al. No difference in cardiovascular risk of tocilizumab versus abatacept for rheumatoid arthritis: a multi-database cohort study. Semin Arthritis Rheum 2018;48:399–405.
38. Kim SC, Solomon DH, Rogers JR, Gale S, Klearman M, Sarsour K, et al. Cardiovascular safety of tocilizumab versus tumor necrosis factor inhibitors in patients with rheumatoid arthritis: a multi-database cohort study. Arthritis Rheumatol 2017;69:1154–64.
39. Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. J Thromb Thrombolysis 2016;41:3–14.
40. Ungprasert P, Srivali N, Wijarnpreecha K, Charoenpong P, Knight EL. Non-steroidal anti-inflammatory drugs and risk of venous thromboembolism: a systematic review and meta-analysis. Rheumatology (Oxford) 2015;54:736–42.
41. Kabrhel C, Varraso R, Goldhaber SZ, Rimm EB, Camargo CA. Prospective study of BMI and the risk of pulmonary embolism in women. Obesity (Silver Spring) 2009;17:2040–6.
42. Mease PJ, Kremer JM, Cohen S, Curtis JR, Charles-Schoeman C, Loftus EV, et al. Incidence of thromboembolic events in the tofacitinib rheumatoid arthritis, psoriasis, psoriatic arthritis and ulcerative colitis development programs [abstract]. Arthritis Rhuematol 2017;69 Suppl 10. URL: https://acrabstracts.org/abstract/incidence-of-thromboembolic-events-in-the-tofacitinib-rheumatoid-arthritis-psoriasis-psoriatic-arthritis-and-ulcerative-colitis-development-programs/.
43. Desai RJ, Pawar A, Weinblatt ME, Kim SC. Comparative risk of venous thromboembolism with tofacitinib versus tumor necrosis factor inhibitors: a cohort study of rheumatoid arthritis patients [abstract]. Arthritis Rheumatol 2018;70 Suppl 10. URL: https://acrabstracts.org/abstract/comparative-risk-of-venous-thromboembolism-with-tofacitinib-versus-tumor-necrosis-factor-inhibitors-a-cohort-study-of-rheumatoid-arthritis-patients/.
44. Burmester GR, Kremer JM, Van den Bosch F, Kivitz A, Bessette L, Li Y, et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2018;391:2503–12.
45. Genovese MC, Fleischmann R, Combe B, Hall S, Rubbert-Roth A, Zhang Y, et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet 2018;391:2513–24.
46. Fleischmann R, Pangan AL, Mysler E, Bessette L, Peterfy C, Durez P, et al. A phase 3, randomized, double-blind study comparing upadacitinib to placebo and to adalimumab, in patients with active rheumatoid arthritis with inadequate response to methotrexate [abstract]. Arthritis Rheumatol 2018;70 Suppl 10. URL: https://acrabstracts.org/abstract/a-phase-3-randomized-double-blind-study-comparing-upadacitinib-to-placebo-and-to-adalimumab-in-patients-with-active-rheumatoid-arthritis-with-inadequate-response-to-methotrexate/.
47. Smolen JS, Cohen S, Emery P, Rigby WF, Tanaka Y, Zhang Y, et al. Upadacitinib as monotherapy: a phase 3 randomized controlled double-blind study in patients with active rheumatoid arthritis and inadequate response to methotrexate [abstract]. Arthritis Rheumatol 2018;70 Suppl 10. URL: https://acrabstracts.org/abstract/upadacitinib-as-monotherapy-a-phase-3-randomized-controlled-double-blind-study-in-patients-with-active-rheumatoid-arthritis-and-inadequate-response-to-methotrexate/.
48. Van Vollenhoven R, Takeuchi T, Pangan AL, Friedman A, Mohamed ME, Chen S, et al. A phase 3, randomized, controlled trial comparing upadacitinib monotherapy to MTX monotherapy in MTX-naïve patients with active rheumatoid arthritis [abstract]. Arthritis Rheumatol 2018;70 Suppl 10. URL: https://acrabstracts.org/abstract/a-phase-3-randomized-controlled-trial-comparing-upadacitinib-monotherapy-to-mtx-monotherapy-in-mtx-naive-patients-with-active-rheumatoid-arthritis/.
49. Genovese MC, Kremer J, Zhong S, Friedman A. Long-term safety and efficacy of upadacitinib (ABT-494), an oral JAK-1 inhibitor in patients with rheumatoid arthritis in an open label extension study [abstract]. Arthritis Rheumatol 2017;69 Suppl 10. URL: https://acrabstracts.org/abstract/long-term-safety-and-efficacy-of-upadacitinib-abt-494-an-oral-jak-1-inhibitor-in-patients-with-rheumatoid-arthritis-in-an-open-label-extension-study/.
50. US Food and Drug Administration. Advisory committee meeting: baricitinib for treatment of moderate to severe rheumatoid arthritis. May 2018. URL: https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM606024.pdf.
51. Weinblatt M, Taylor PC, Burmester GR, Witt S, Saifan C, Walls C, et al. Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis [abstract]. Arthritis Rheumatol 2017;69 Suppl 10. URL: http://acrabstracts.org/abstract/cardiovascular-safety-during-treatment-with-baricitinib-in-rheumatoid-arthritis/.
52. Weinblatt M, Taylor PC, Burmester GR, Saifan C, Walls CD, Issa M, et al. Cardiovascular safety–update from up to 6 years of treatment with baricitinib in rheumatoid arthritis clinical trials [abstract]. Arthritis Rheumatol 2018; 70 Suppl 10. URL: http://acrabstracts.org/abstract/cardiovascular-safety-update-from-up-to-6-years-of-treatment-with-baricitinib-in-rheumatoid-arthritis-clinical-trials/.